Host sphingolipid biosynthesis is a promising therapeutic target for the inhibition of hepatitis B virus replication.
about
Serum sphingolipids reflect the severity of chronic HBV infection and predict the mortality of HBV-acute-on-chronic liver failureSphingolipid and ceramide homeostasis: potential therapeutic targets.Serum Sphingolipid Variations Associate with Hepatic Decompensation and Survival in Patients with Cirrhosis.Entry of hepatitis B virus into immortalized human primary hepatocytes by clathrin-dependent endocytosis.Serum lipid alterations identified in chronic hepatitis B, hepatitis B virus-associated cirrhosis and carcinoma patients.Antihepatitis B therapy: a review of current medications and novel small molecule inhibitors.Chimeric rodents with humanized liver: bridging the preclinical/clinical trial gap in ADME/toxicity studies.Importance of endocytic pathways in liver function and disease.Everybody needs sphingolipids, right! Mining for new drug targets in protozoan sphingolipid biosynthesis.Compounds of the sphingomyelin-ceramide-glycosphingolipid pathways as secondary messenger molecules: new targets for novel therapies for fatty liver disease and insulin resistance.Myriocin prevents muscle ceramide accumulation but not muscle fiber atrophy during short-term mechanical unloading.Variations in serum sphingolipid levels associate with liver fibrosis progression and poor treatment outcome in hepatitis C virus but not hepatitis B virus infection.Current landscape and future prospects of antiviral drugs derived from microbial products.
P2860
Q34066622-4EA6B3A4-7D2A-4195-8BAA-DC5F0FB9D4FBQ35778875-785642D1-CE6F-4122-B82F-D51BEF5A320FQ35780081-4423B5A3-59AF-4B2A-AD8A-65B7B0F03073Q36154830-61D55DE1-82FD-4AA6-8BC1-53EC5E334EF5Q37642807-1BE0CC98-7C0B-4944-A156-01704BEDD5AEQ38151881-43730EC5-7766-4385-843D-43002A01B875Q38169790-1A1046F8-2ADD-4C36-A899-23B2635CB9AFQ38271904-8E9272F7-DB65-42C0-92FE-E13B27D8C78DQ38668340-78AB49E9-E892-425E-8FF7-3660845044E2Q38833111-B7F2D712-B2F7-47BE-85A2-3E7CEC5D9BD4Q40350492-51FE365E-B75B-43D8-A754-6F69F93D49E3Q41687237-4BB68059-5F7C-4109-A756-C0EF7BBB489FQ41919714-A8E48994-FFB1-4DF6-A792-9582DDC13A94
P2860
Host sphingolipid biosynthesis is a promising therapeutic target for the inhibition of hepatitis B virus replication.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Host sphingolipid biosynthesis ...... hepatitis B virus replication.
@en
Host sphingolipid biosynthesis ...... hepatitis B virus replication.
@nl
type
label
Host sphingolipid biosynthesis ...... hepatitis B virus replication.
@en
Host sphingolipid biosynthesis ...... hepatitis B virus replication.
@nl
prefLabel
Host sphingolipid biosynthesis ...... hepatitis B virus replication.
@en
Host sphingolipid biosynthesis ...... hepatitis B virus replication.
@nl
P2093
P2860
P356
P1476
Host sphingolipid biosynthesis ...... hepatitis B virus replication.
@en
P2093
Kanako Tatematsu
Masashi Mizokami
Masaya Sugiyama
Masayuki Sudoh
Yasuhito Tanaka
P2860
P304
P356
10.1002/JMV.21970
P577
2011-04-01T00:00:00Z